Regularly, HOXA11-AS lncRNA is a tumor-suppressor that inhibits EOC proliferation and migration; however, in many EOC cases, researchers observed downregulation of the lncRNA in the ovarian tissue. HOXA11-AS has been shown to be significantly up-regulated in gastric cancer tissue cells. The increase in expression of HOXA11-AS promotes cancer cell migration, tumor cell invasion, as well as metastasis of gastric cancer cells. HOXA11-AS has also been shown to affect cell apoptosis. Research that investigates the mechanism for the upregulation of HOXA11-AS shows that it specifically promotes transcription of beta-catenin through its interaction with EZH2. Additionally, current research has found that HOXA11-AS interacts with miR-1297 and blocks its ability to repress EZH2 protein translation. Tissue samples from patients with colorectal cancer (CRC) were observed to have decreased expression of HOXA11-AS lnRNA when compared to normal colon cells. Correlations were seen between patients with larger tumor size, higher carcinoembryonic antigen (CEA), and increased metastases to decreased expression of the lncRNA. These metastases were tumor-node metastases (TNM) and lymphatic metastases. Lymphatic metastases is significant, as it is a common route for cancer cells to migrate to other parts of the body. Scientists were able to determine the effect HOXA11-AS lnRNA had on migration by blocking the transcript with siRNA and observing decreased cell migration and invasion. There was no correlation found between the migration distance and decreased HOXA11-AS lnRNA expression.